Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?

about

Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?

Item

http://www.wikidata.org/entity/Q39215476

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Is there a role for a maintena ...... ther than follicular lymphoma?

@en

Is there a role for a maintena ...... ther than follicular lymphoma?

@nl

type

Item

label

Is there a role for a maintena ...... ther than follicular lymphoma?

@en

Is there a role for a maintena ...... ther than follicular lymphoma?

@nl

prefLabel

Is there a role for a maintena ...... ther than follicular lymphoma?

@en

Is there a role for a maintena ...... ther than follicular lymphoma?

@nl

P1476

Is there a role for a maintena ...... ther than follicular lymphoma?

@en

P2093

Alden A Moccia

http://www.w3.org/2001/XMLSchema#string

Michele Ghielmini

http://www.w3.org/2001/XMLSchema#string

P2860

Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study

Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

Treatment of older patients with mantle-cell lymphoma.

Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network.

Guidelines on the management of Waldenström macroglobulinaemia.

P304

30-36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2016.1248963

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Emanuele Zucca

P577

2016-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27813427

http://www.w3.org/2001/XMLSchema#string